StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$3.01−0.37 (-10.81%)

Close on Nov 17, 2026Market cap $58.22MP/E –Yield –

Corbus Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Corbus Pharmaceuticals's cash was $117.94M at Jun 30, 2026. For fiscal 2025 it was $163.27M, up 9.5% from the year before. Over ten years it grew 29.4% a year on average. The highest annual figure on record is $163.27M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$163.27M+9.5%
FY2024Dec 31, 2024$149.06M+613.0%
FY2023Dec 31, 2023$20.91M-64.7%
FY2022Dec 31, 2022$59.20M-39.4%
FY2021Dec 31, 2021$97.65M+14.3%
FY2020Dec 31, 2020$85.43M+169.1%
FY2019Dec 31, 2019$31.75M-24.0%
FY2018Dec 31, 2018$41.75M-33.4%
FY2017Dec 31, 2017$62.70M+312.7%
FY2016Dec 31, 2016$15.19M+22.8%
FY2015Dec 31, 2015$12.37M+97.2%
FY2014Dec 31, 2014$6.28M+1971.2%
FY2013Dec 31, 2013$303.02K-44.1%
FY2012Dec 31, 2012$542.48K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$117.94M+1.2%
Q1 FY2026Mar 31, 2026$138.22M+4.1%
Q4 FY2025Dec 31, 2025$163.27M+9.5%
Q3 FY2025Sep 30, 2025$103.98M-34.8%
Q2 FY2025Jun 30, 2025$116.59M-20.7%
Q1 FY2025Mar 31, 2025$132.79M+10.6%
Q4 FY2024Dec 31, 2024$149.06M+613.0%
Q3 FY2024Sep 30, 2024$159.36M+454.6%
Q2 FY2024Jun 30, 2024$147.03M+302.1%
Q1 FY2024Mar 31, 2024$120.10M+171.6%
Q4 FY2023Dec 31, 2023$20.91M-64.7%
Q3 FY2023Sep 30, 2023$28.73M-56.6%
Q2 FY2023Jun 30, 2023$36.57M-50.1%
Q1 FY2023Mar 31, 2023$44.23M-48.6%
Q4 FY2022Dec 31, 2022$59.20M-39.4%
Q3 FY2022Sep 30, 2022$66.23M-38.0%
Q2 FY2022Jun 30, 2022$73.30M-31.1%
Q1 FY2022Mar 31, 2022$86.12M-30.6%
Q4 FY2021Dec 31, 2021$97.65M+14.3%
Q3 FY2021Sep 30, 2021$106.86M+30.5%
Q2 FY2021Jun 30, 2021$106.45M+67.7%
Q1 FY2021Mar 31, 2021$124.01M+166.0%
Q4 FY2020Dec 31, 2020$85.43M+169.1%
Q3 FY2020Sep 30, 2020$81.87M+49.3%
Q2 FY2020Jun 30, 2020$63.47M-13.2%
Q1 FY2020Mar 31, 2020$46.62M-48.2%
Q4 FY2019Dec 31, 2019$31.75M-24.0%
Q3 FY2019Sep 30, 2019$54.85M-1.5%
Q2 FY2019Jun 30, 2019$73.15M+13.1%
Q1 FY2019Mar 31, 2019$89.92M+26.7%
Q4 FY2018Dec 31, 2018$41.75M-33.4%
Q3 FY2018Sep 30, 2018$55.66M+51.3%
Q2 FY2018Jun 30, 2018$64.68M+49.6%
Q1 FY2018Mar 31, 2018$70.96M+44.4%
Q4 FY2017Dec 31, 2017$62.70M+312.7%
Q3 FY2017Sep 30, 2017$36.80M+92.7%
Q2 FY2017Jun 30, 2017$43.23M–
Q1 FY2017Mar 31, 2017$49.13M–
Q4 FY2016Dec 31, 2016$15.19M–
Q3 FY2016Sep 30, 2016$19.10M–

More Corbus Pharmaceuticals figures

See a number that looks wrong?